# Role of Toll-Like Receptors in the interplay between pathogen and damage   associated molecular patterns

**Authors:** S. Chatterjee, B. S. Sanjeev

arXiv: 1907.03512 · 2019-07-09

## TL;DR

This study investigates how Toll-Like Receptors (TLRs) mediate interactions between pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), highlighting their crucial role in immune response and potential therapeutic targets.

## Contribution

It identifies the pivotal role of TLRs in pathogen-host interactions, especially in recognizing PAMPs and DAMPs, and suggests new therapeutic strategies for inflammatory diseases.

## Key findings

- TLRs are central in pathogen and damage pattern recognition.
- SOD1 and SOD2 are key in mitigating oxidative stress.
- Potential for new anti-inflammatory therapies.

## Abstract

Various theoretical studies have been carried out to infer relevant protein-protein interactions among pathogens and their hosts. Such studies are generally based on preferential attachment of bacteria / virus to their human receptor homologs. We have analyzed 17 pathogenic species mainly belonging to bacterial and viral pathogenic classes, with the aim to identify the interacting human proteins which are targeted by both bacteria and virus specifically. Our study reveals that the TLRs play a crucial role between the pathogen-associated molecular patterns (PAMPs) and the damage associated molecular patterns (DAMPS). PAMPs include bacterial lipopolysaccharides (LPs), endotoxins, bacterial flagellin, lipoteichoic acid, peptidoglycan in bacterial organisms and nucleic acid variants associated with viral organisms, whereas DAMPs are associated with host biomolecules that perpetuate non-infectious inflammatory responses. We found out the presence of SOD1 and SOD2 (superoxide dismutase) is crucial, as it acts as an anti-oxidant and helps in eliminating oxidative stress by preventing damage from reactive oxygen species. Hence, such strategies can be used as new therapies for anti-inflammatory diseases with significant clinical outcomes.

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/1907.03512/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/1907.03512/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/1907.03512/full.md

---
Source: https://tomesphere.com/paper/1907.03512